Vistagen Therapeutics Inc
(VTGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2013 | 05-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 90 | 638 | 638 | 24 | 13 |
| TOTAL | $225 | $672 | $672 | $107 | $328 |
| Non-Current Assets | |||||
| PPE Net | 178 | 181 | 181 | 189 | 67 |
| Other Non-Current Assets | 29 | 29 | 29 | 30 | 29 |
| TOTAL | $207 | $210 | $210 | $219 | $96 |
| Total Assets | $432 | $882 | $882 | $326 | $425 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,759 | 1,354 | 1,354 | 1,252 | 1,474 |
| Accrued Expenses | 371 | 343 | 343 | 382 | 394 |
| TOTAL | $2,933 | $2,414 | $2,414 | $2,576 | $2,945 |
| Non-Current Liabilities | |||||
| Long Term Debt | 3,327 | 3,198 | 3,198 | 2,960 | 1,103 |
| Other Non-Current Liabilities | 6,116 | 7,820 | 7,820 | 5,305 | 2,825 |
| TOTAL | $9,447 | $11,024 | $11,024 | $8,272 | $3,937 |
| Total Liabilities | $12,381 | $13,438 | $13,438 | $10,848 | $6,882 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 726 | N/A | 708 | 669 | 578 |
| Common Shares | 24 | 24 | 24 | 22 | 20 |
| Retained earnings | -67,484 | -67,669 | -67,669 | -63,899 | -58,564 |
| Other shareholders' equity | -177 | -177 | -177 | -224 | -198 |
| TOTAL | $-11,949 | $-12,556 | $-12,556 | $-10,522 | $-6,458 |
| Total Liabilities And Equity | $432 | $882 | $882 | $326 | $425 |